Table 1.
Baseline patient and disease characteristics [n (%)]
| Parameter | PLI+RFA group (n=24) | PEI+RFA group (n=17) | χ2/t | P value |
|---|---|---|---|---|
| Age# (mean ± SD), years | 55.3 ± 9.8 | 54.1 ± 9.7 | 0.380 | 0.706 |
| Sex | 0.007 | 1.000 | ||
| Male | 20 (75) | 14 (82.4) | ||
| Female | 4 (25) | 3 (17.6) | ||
| ECOG PS score | 0.191 | 1.000 | ||
| 0 | 20 (75) | 15 (88.2) | ||
| 1 | 4 (25) | 2 (11.8) | ||
| Child-Pugh class | 0.017 | 0.896 | ||
| A | 16 (66.7) | 11 (64.7) | ||
| B | 8 (33.3) | 6 (35.3) | ||
| Hepatitis virus status | 0.562 | 0.755 | ||
| HBV | 20 (83.3) | 15 (88.2) | ||
| HCV | 3 (12.5) | 1 (5.9) | ||
| non-HBV or HCV | 1 (4.2) | 1 (5.9) | ||
| BCLC stage | 0.133 | 1.000 | ||
| A | 22 (91.7) | 15 (88.2) | ||
| B | 2 (8.3) | 2 (11.8) | ||
| Number of liver tumors | 0.236 | 0.889 | ||
| 1 | 19 (79.2) | 14 (82.4) | ||
| 2 | 4 (16.7) | 2 (11.8) | ||
| 3 | 1 (4.2) | 1 (5.9) | ||
| High-risk location | 0.139 | 0.998 | ||
| Abutting gastrointestinal tract | 4 (13.3) | 3 (14.3) | ||
| Abutting heart and diaphragm | 6 (20.0) | 5 (23.8) | ||
| Abutting major vessels | 6 (20.0) | 4 (19.0) | ||
| Abutting gallbladder | 3 (10.0) | 2 (9.5) | ||
| Abutting hepatic capsule | 11 (36.7) | 7 (33.3) | ||
| Tumor growth pattern | 0.706 | 0.401 | ||
| With capsule | 12 (40.0) | 6 (28.6) | ||
| Infiltrative | 18 (60.0) | 15 (71.4) | ||
| Largest diameter#, cm | 3.0 ± 0.9 | 2.9 ± 1.0 | 0.490 | 0.627 |
| AFP (ng/ml)# | 404.1 ± 549.8 | 266.0 ± 203.6 | 0.986 | 0.330 |
| ≥ 200 ng/ml | 14 (58.3) | 10 (58.8) | 0.001 | 0.975 |
| TACE treatment | 0.133 | 1.000 | ||
| yes | 22 (91.7) | 15 (88.2) | ||
| no | 2 (8.3) | 2 (11.8) |
Except where indicated, data are numbers of patients, with percentages in parentheses.
#
t-test, data are means ± standard deviations; ECOG PS, Eastern Cooperative Oncology Group performance status; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, a-fetoprotein; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.